LYPD1

Across TCGA pan-cancer cohorts, LYPD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYPD1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LYPD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYPD1 expression acts as an unfavorable survival marker.

OV, STAD, and SKCM are the cancer types where LYPD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	12	view →
SKCM	OS	Median	All	0.283	0.787	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LYPD1–OV (OS)

Open the OV breakdown →